Market Overview

UPDATE: Morgan Stanley Upgrades Medtronic Following Acquisition Of COV

Share:
Related MDT
Medtronic CEO: Covidien Merger Has Accelerated Growth Strategy
Medtronic, Inc.: Medtronic Drug-Coated Balloon for Peripheral Artery Disease Tops Standard Balloon Angioplasty in Landmark
Medtronic Completes Covidien Acquisition for $50B - Analyst Blog (Zacks)

In a report published Tuesday, Morgan Stanley analyst David R. Lewis upgraded the rating on Medtronic (NYSE: MDT) from Equal-Weight to Overweight, and named a $73.00 price target.

In the report, Morgan Stanley noted, “We are upgrading MDT to Overweight following its transformational acquisition of COV. The initial muted reaction (-1%) fails to appreciate greater financial upside through cost and tax synergies and peer leading capital deployment flexibility which should drive >10% returns.”

Medtronic closed on Monday at $60.03.

Latest Ratings for MDT

DateFirmActionFromTo
Dec 2014Bank of AmericaMaintainsBuy
Nov 2014WedbushMaintainsNeutral
Nov 2014JefferiesMaintainsBuy

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Upgrades Analyst Ratings

 

Related Articles (MDT)

Around the Web, We're Loving...

Get Benzinga's Newsletters